Omeprazole and Gastroprotectants in Dogs: ACVIM Consensus, Overprescription Evidence, and Drug Interactions

Bottom line

• Proton pump inhibitors (PPIs) are the most commonly prescribed gastroprotectant class in small animal practice — 50.6% of respondents in a 265-veterinarian Spanish survey — yet injudicious use for conditions lacking robust evidence remains well documented as of July 2026.[1]
• The 2018 ACVIM consensus statement on rational use of gastrointestinal protectants is the governing evidence framework; it explicitly discourages reflexive, indication-poor PPI prescribing and reserves acid suppression for defined indications.[4]
• Publishing that consensus measurably changed behaviour: at a veterinary teaching hospital, ACVIM-aligned omeprazole prescriptions rose significantly (p<0.0001) and 94% (15/16) of prescribers reported changing practice after reading it.[2]
• Long-term omeprazole in healthy dogs significantly raises serum gastrin (p=0.008, rebound hypergastrinaemia) but did not significantly change cobalamin over 60 days in an RCT — so taper after prolonged therapy, but the human B12-deficiency concern does not transfer directly to dogs.[3]
• In healthy cats, concurrent omeprazole lowers the clopidogrel active metabolite (P<.02) but did not change platelet function on 2 of 3 assays over short-term use — a real PK signal with limited measured PD consequence in healthy animals.[5]

Drug facts

Class / mechanism. Omeprazole is a substituted benzimidazole proton pump inhibitor. It irreversibly inhibits the gastric H+/K+-ATPase (proton pump) on the luminal surface of parietal cells, producing profound, durable suppression of gastric acid secretion that outlasts the plasma half-life (new pump synthesis is required to restore acid output). This makes PPIs the most potent acid-suppressing class available for dogs and cats and the reference standard where meaningful intragastric pH elevation is the therapeutic goal.[4]

Indications (evidence-based, per ACVIM consensus). Acid suppression is warranted for documented or strongly suspected gastroduodenal ulceration/erosion, reflux/reflux oesophagitis, and gastrinoma or other hyperacidity states; and for gastrointestinal bleeding of appropriate cause. Co-administration with ulcerogenic drugs is justified when additional risk factors are present, not reflexively. Routine gastroprotection for every NSAID-treated dog is explicitly not supported.[4]

Approval / availability. Omeprazole is used in dogs and cats largely off-label from human formulations; over-the-counter availability in many markets increases owner-initiated and clinician overprescription, which the consensus flags as a driver of inappropriate use.[4]

Contraindications / cautions (headline). Avoid abrupt discontinuation after prolonged therapy (rebound hyperacidity from hypergastrinaemia); use judiciously with drugs whose activation or absorption is pH- or CYP-dependent (see PK section). Full precautions and interactions are detailed below.[3][4]

Is omeprazole overprescribed, and did the ACVIM consensus change prescribing? (efficacy of the guideline)

Overprescription of PPIs is a recognised quality indicator in human medicine, and the same pattern is documented in veterinary practice. As of July 2026, the largest real-world snapshot is Olmeda et al. 2026, a 265-veterinarian online snowball survey in Spain characterising gastroprotectant prescribing in dogs. PPIs were the most commonly prescribed class (50.6% of participants). While most main indications respondents cited were supported by scientific evidence, injudicious administration for disorders lacking robust evidence or recommendations was well documented. Veterinarians with fewer years of clinical experience and those working in internal medicine, emergency, and anaesthesia were more likely to adhere to evidence-based guidelines; clinicians who prescribed gastroprotectants less frequently tended to rely on PPIs and on international consensus guidelines.[1]

That survey captures broad primary-practice behaviour and complements a focused before-and-after study of guideline impact. Sainz et al. 2024 compared omeprazole prescribing at a veterinary teaching hospital in the periods surrounding the 2018 ACVIM consensus (2021 vs 2017). Prescriptions aligned with ACVIM-supported indications increased significantly in the post-consensus period (p<0.0001), the frequency of appropriate tapering after ≥4-week therapy increased significantly, and 15 of 16 prescribing clinicians (94%) reported that reading the consensus changed their clinical practice regarding PPI administration.[2]

Synthesis. The two datasets are complementary, not contradictory: Sainz shows the consensus works where clinicians engage with it (an academic setting), while Olmeda shows that 6+ years after publication, overprescription persists across general practice — particularly for indications such as routine NSAID co-administration without additional risk factors. The observation that internal-medicine, emergency, and anaesthesia clinicians adhere better plausibly reflects greater continuing-education engagement with consensus statements and supports targeted, specialty-aware education. Actionable read: review indication appropriateness at every prescription, and audit tapering practice specifically.[1][2][4]

Does long-term omeprazole cause metabolic or endocrine effects in dogs? (safety / adverse effects)

The controlled dog data come from Gil-Vicente et al. 2024, a prospective randomised controlled clinical trial enrolling 18 healthy dogs (10 control, 8 omeprazole) with sampling at baseline, 30 days, and 60 days.[3]

• Gastrin. Serum gastrin rose significantly in the omeprazole group (median 67.59 pg/mL at baseline vs 191.77 pg/mL at T1; p=0.008), consistent with the expected rebound hypergastrinaemia that follows sustained acid suppression. Clinically this underpins the recommendation to taper rather than abruptly stop after prolonged courses, because withdrawal against an elevated gastrin drive can produce rebound hyperacidity.[3]
• Cobalamin. No statistically significant change in cobalamin (B12) was seen in either group across 60 days. This contrasts with human medicine, where prolonged PPI use has been associated with B12 deficiency, and suggests the cobalamin concern does not transfer directly to dogs over this horizon.[3]

Synthesis with the consensus. The ACVIM consensus already cautions that long-term PPI use carries documented adverse effects and should not be open-ended.[4] The dog RCT sharpens this for the clinician: the monitorable, mechanism-linked signal in dogs is gastrin (and its rebound implication), not cobalamin. Longer courses and larger populations may yet reveal effects the 60-day, n=18 study was not powered to detect, so absence of a cobalamin signal here is reassuring but not definitive.[3]

Does omeprazole interfere with clopidogrel? (drug interaction — contested)

This is a frequently asked interaction because in humans the clopidogrel–omeprazole combination is a recognised concern: both involve overlapping hepatic CYP pathways (clopidogrel is a prodrug requiring CYP-mediated activation; omeprazole inhibits CYP2C19), and reduced clopidogrel activation can blunt antiplatelet effect. Whether this matters in cats was unclear until Plante et al. 2024, a 2-sequence, 2-period randomised crossover study: ten healthy cats received clopidogrel alone or clopidogrel plus omeprazole for 10 days each, separated by a washout.[5]

Two findings that must be held together:

• The PK signal is real. Plasma clopidogrel active-metabolite concentrations were significantly lower on day 10 with concurrent omeprazole versus clopidogrel alone (P<.02) — directionally consistent with the human interaction.[5]
• The measured PD effect was small. Despite the metabolite drop, two of three platelet-function assays (Multiplate Analyzer and PFA-100) detected no difference in platelet function between treatments over short-term use. The authors concluded the combination altered pharmacokinetics but did not appear to significantly alter platelet function in healthy cats.[5]

Neutral synthesis. The interaction is pharmacokinetically demonstrable but its short-term antiplatelet consequence in healthy cats appears limited. Critically, the study enrolled healthy cats over a short period, so it cannot exclude clinically meaningful attenuation in cats with active thrombotic disease (e.g., cardiogenic arterial thromboembolism) or on prolonged combined therapy — precisely the population in which clopidogrel matters most. Where a PPI is genuinely indicated in a clopidogrel-treated cat, this evidence tempers alarm but does not license complacency; if acid suppression is not clearly indicated, the cleanest move is to avoid the co-prescription rather than rely on unmeasured PD reserve.[4][5]

Contraindications, precautions & PK

• Rebound hyperacidity / hypergastrinaemia. Sustained acid suppression drives a compensatory rise in gastrin (demonstrated in dogs at p=0.008); abrupt withdrawal after prolonged therapy risks rebound hyperacidity. Taper after ≥4 weeks rather than stopping abruptly, per consensus and the RCT rationale.[3][4]
• pH-dependent drug interactions. Because omeprazole markedly raises intragastric pH, absorption of drugs requiring an acidic environment (e.g., certain azole antifungals, some tyrosine-kinase inhibitors, iron salts) can be reduced. Weigh this when co-prescribing.[4]
• CYP-mediated interactions (clopidogrel). Omeprazole reduced the clopidogrel active metabolite in cats (P<.02); short-term platelet function was preserved on 2/3 assays, but caution applies in thrombotic disease or long-term use. Consider the interaction explicitly in cardiology patients.[5]
• Cobalamin. No significant 60-day change in dogs; routine B12 monitoring is not mandated by the dog data, though prolonged/large-population effects are not excluded.[3]
• Duration discipline. Long-term PPI use carries documented adverse effects; the consensus favours the shortest effective course for a defined indication, not indefinite prophylaxis.[4]

Practical decision support

• Prescribe to an indication, not a reflex. Reserve omeprazole for documented gastroduodenal ulceration/erosion, reflux oesophagitis, hyperacidity states, and appropriate GI bleeding — not for every NSAID course. Add gastroprotection to an NSAID only when additional risk factors are present.[4]
• Audit your own overprescription. Given persistent overprescription across general practice as of July 2026, treat "is this indication actually evidence-supported?" as a checklist item at each prescription.[1]
• Taper, don't stop cold. After ≥4 weeks, taper to blunt rebound hypergastrinaemia/hyperacidity; appropriate tapering is a measurable behaviour that improved post-consensus.[2][3]
• In clopidogrel-treated cats, decide the PPI on its own merits. If a PPI is genuinely indicated, short-term co-use appears tolerable on current healthy-cat data; if it is not clearly indicated, avoid it rather than bank on preserved platelet function in a thrombotic patient.[5]
• Confirm dosing at point of care. This is an evidence summary, not a prescribing protocol; verify current dose, frequency, formulation, and interaction guidance in Plumb's Veterinary Drug Handbook and the primary sources before prescribing.

Frequently Asked Questions

Are PPIs the most commonly prescribed gastroprotectant in dogs? Yes. In a 265-veterinarian survey in Spain, PPIs were the most commonly prescribed gastroprotectant class (50.6% of participants), though injudicious use for indications lacking robust evidence was also documented.[1]

Did the 2018 ACVIM consensus actually change prescribing? At a veterinary teaching hospital, ACVIM-aligned omeprazole prescriptions increased significantly (p<0.0001), tapering after prolonged therapy improved, and 94% of prescribers (15/16) reported changing their practice after reading the consensus.[2][4]

Does long-term omeprazole raise gastrin in dogs? Yes. In a prospective RCT in healthy dogs, serum gastrin rose significantly after omeprazole (median 67.59 → 191.77 pg/mL; p=0.008), reflecting rebound hypergastrinaemia — a key reason to taper rather than stop abruptly.[3]

Does long-term omeprazole cause cobalamin (B12) deficiency in dogs? The same RCT found no statistically significant change in cobalamin over 60 days in healthy dogs, contrasting with human medicine; routine B12 monitoring is not mandated by these dog data.[3]

Should all NSAID-treated dogs receive gastroprotection? No. The ACVIM consensus explicitly does not recommend routine gastroprotection for every NSAID-treated dog; reserve it for cases with additional risk factors or documented gastroduodenal lesions.[4]

Does omeprazole interfere with clopidogrel in cats? In a crossover study of 10 healthy cats, concurrent omeprazole significantly lowered the clopidogrel active metabolite on day 10 (P<.02), but 2 of 3 platelet-function assays (Multiplate, PFA-100) showed no difference in platelet function over short-term use.[5]

Is the omeprazole–clopidogrel interaction clinically important in cats? The pharmacokinetic effect is real but the short-term platelet-function consequence appeared small in healthy cats. Because the study used healthy cats over a short period, caution is warranted before generalising to cats with thrombotic disease or on long-term combined therapy.[5]

How long should omeprazole be continued, and how should it be stopped? Use the shortest effective course for a defined indication; after ≥4 weeks, taper rather than discontinue abruptly to blunt rebound hyperacidity driven by hypergastrinaemia.[3][4]

Changelog

• 2026-07-06: Consolidated the omeprazole/gastroprotectants cluster into this evergreen hub. Folded in the 265-vet Olmeda 2026 overprescription survey and the Plante 2024 feline clopidogrel–omeprazole crossover RCT (both previously standalone dated dispatches), and elevated the 2018 ACVIM consensus (Marks et al.) to a primary, directly cited source. Reorganised evidence by clinical question and added contraindications/PK and decision-support sections.
• 2026-06-19: First published.